leadf
logo-loader
viewQ BioMed Inc.
(
OTCQB:QBIO
)

Q BioMed Inc 'thrilled' with $30M insider investment to help advance its pipeline of therapeutics

Q BioMed Inc (OTCQB:QBIO) CEO Denis Corin tells Proactive the privately held global disruption aggregator Aedesius Holdings Ltd, run by Geoffrey Fatzinger, Q BioMed's global head of regulatory affairs, has committed to investing up to $30 million in the company via a securities agreement. Corin says its the largest single investment so far for the biotech, allowing the group to move forward with its commercial roll-out plans for its cancer bone pain drug Strontium89, as well as advance its development opportunities.

Quick facts: Q BioMed Inc.

Follow
OTCQB:QBIO

Price: 0.70215 USD

Market Cap: $19.37 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of named herein, including the promotion by the Company of in any Content on the Site, the Company receives from said issuer annual cash...

FOR OUR FULL DISCLAIMER CLICK HERE

Q BioMed and Mannin Research move forward with MAN-19 therapeutic

Q BioMed Inc CEO Denis Corin, CEO and Mannin Research Inc CEO Dr George Nikopoulos joined Proactive's Stephen Gunnion with news that the companies are poised to start clinical trials of their MAN-19 therapeutic in 2022. The MAN-19 therapeutic is a recombinant fusion protein and is being...

3 days ago

2 min read